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The long-term follow-up study (41 ± 23 meaths) of 47
patients undergoing direct current ablation because of
drugresistent supraventricular arrhythndas is reported .
Significant early complications occurred in four patients
and included hypotension, pericarditis, nonsustained poly .
morphic ventricular taehycardia and one sudden death . In
42 patients (86%), complete atrioventricular (AV) block
was initially achieved . During the follow-up period, AV
conduction resumed In 2 of these 42 patients . Of the seven
patients in whom ablation was unsuccessful, two developed
late complete AV block and three bad symptomatic im-
provement.
An Improved activity level was reported among 83% of
the patients with successful ablation . Health care utilization
manifest as the number of hospital admissions per year
before and after ablation decreased significantly after ab-
lation (2,4 t 2 .0 versus 0.3 t 0,5, p < 0.001) . Echocar-
diographic evaluation in live patients with a depressed left
Transcatheter direct current ablation of the atrioventricular
(AV) junction is an established method for treating patients
with supraventricular arrhythmias who do not respond to
drug therapy (1-4) . To date, the largest experience with this
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ventricular ejection fraction (27 t 7%) before ablation
showwt a significant increase (45 ± 14%, p < 0.05) after an
average follow-up period of 31 months . New onset of
congestive heart failure occurred after ablation in four
patients, of whom two had no structural heart disease . The
total mortality rate, including the one patient with sudden
death, was 17)5 and was significantly higher among pa-
tients with underlying structural heart disease .
Transcatheter direct current ablation is an effective
treatment in patients with drug-resistant supraventricular
tachycardia, providing a beneficial long-term outcome in-
cluding an improved quality of life and a decrease in health
care utilization. Became of the small but significant risk of
seven complications, this procedure should be reserved for
patients with supraventricular arrhythmias who do not
respond to conventional drug treatment .
fJ Am Coil Cordial 1995;16c1407-74)
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technique has been provided by a voluntary registry (5) . The
drawbacks of this registry include retrospective analysis of
data, lack of quality control in data procurement and differ-
ences in techniques for the ablative procedure itself
. In
addition, little information is available relating to long-term
follow-up study and changes in left ventricular performance
.
Although this procedure provides for control of disabling
arrhythmias, it is associated with certain risks and requires
permanent cardiac pacing . In addition, because most pa-
tients undergoing catheter ablation have persistent atria)
arrhythmias, the risk of systemic embolization is still
present
. Thus, overall long-term benefits of this treatment
are uncertain .
Catheter ablation of the AV junction was first performed
in 1981 (ll . Because a substantial number of patients have
now been followed up for several years, it is important to
review the experience from our center with respect to the
0735-I09790<3 .S0
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Tahk 1. Clinical Chaomctcristics of49 Patients Before Abtarion
AVNRT = etrioventricular (AV) node reentrant Ischycardia ; AVRT =
AV reciprocating Iachycardia ; DC = direct cvnenC HR = heart ate;
LVEF = left ventricular ejection fraction .
effects of ablation of the AV junction on arrhythmia control
and quality of life, including health care utilization and
ventricular performance .
Methods
Study patients (Table 1), During the time period from
March 1981 to May 1988, 49 patients at the University
of
California, San Francisco, underwent ablation of the AV
junction because of intractable supraventricular arrhyth-
mias . Patients were considered candidates for the procedure
if persistent disabling supraventricular tachycardia had
failed to respond to pharmacologic therapy
. All surviving
patients with follow-up study of at least I year's duration
were included in this study . Two patients were lost to
follow-up evaluation. The mean age was 54 years (range 20
'o 77) and 56% were men . Structural heart disease was
present in 54%
. The mean left ventricular ejection fraction
was 48 ± 13%
; eight patients had an ejection fraction <45% .
Atria) fibrillation or flutter, or both, was present in 59%, AV
node reentrant tachycardia in 26%p, orthodromic supraven-
tricular tachycardia mediated by a concealed accessory
pathway in 12
.5% and atrial tachycardia in 2 .5% .
Symptomatic tachycardia had been present for a mean of
12.6 ± 14.0 years (range I to 57) and resulted in syncope in
29% of
the patients and cardiac arrest in 8% . The mean heart
rate during tachycardia was 177 ± 42 beats/min (range 100 to
300) and external direct current countershock was necessary
for 53% of the patients. The frequency of tachycardia
episodes is shown in Table I . The patients had not re-
sponded to or had been intolerant of a mean of 5
.5 t 2 drugs
(range I to 12) (Table 1) .
Ablation procedure. A 6F quadripolar electrode catheter
(USCI) was introduced into the femoral vein and positioned
across the tricuspid valve to record the largest His bundle
potential between the distal electrodes
. The catheter was
manipulated so that the largest unipolar unfiltered His bun-
dle deflection was recorded from the distal electrode . An-
other quadripolar electrode catheter was inserted from the
femoral vein and placed against the right ventricular apex for
temporary pacing. The distal electrode was used as the
cathode for ablation, and a large skin electrode (132 Corpo-
ration) was placed over the left scapula and used as the
anode.
A short-acting anesthetic agent was administered and one
or more synchronized shocks were delivered
. The defibril-
lator was set at 200 to 300 J per shock and up to five shocks
were delivered until persistent complete AV block was
achieved . One additional shock of 200 J was always given,
even if complete AV block was produced by the initial
shock. After a successful procedure, temporary ventricular
pacing was instituted from the right ventricular apex, and the
patient was observed in the electrophysiology laboratory for
at least 20 min to confirm that complete AV block persisted
.
The patient was then transferred to the coronary care unit
for continued observation . If complete AV block persisted
after 24 h, a permanent pacemaker was inserted .
If complete AV block was not achieved after five shocks,
the session was stopped and the patient brought back to the
electrophysiology laboratory the next day for a second
session. If recurrence of AV conduction occurred before
discharge, the patient underwent a repeat procedure
.
Follow-up pi sndure. All patients available for follow-up
study and their physicians were interviewed with respect to
symptoms, prescribed medications, number of hospital ad-
missions and new cardiovascular events during the follow-up
period. Patients were asked to compare their functional
status with that before ablation . The New York Heart
Association classification with respect to symptoms of con-
gestive heart failure was assessed before and after ablation
.
Health care utilization before and after ablation was defined
Mean ago (yr) 54 ± 351lange
20-77)
Male gender
27 (56%)
DC conversion required 2603%)
Duration of symptoms (yr) 12
.6 x 14 (range 1-57)
lachemic heart disease
11(23%)
Cardiomyapathy
14(29%)
LVEF (%) 48 ± 13 (range IS-651
Types of anhylhmias
Aldalfibrillationlautter 29(59%)
AVNRT
13 (26%)
AVRT 6 (12 .5%)
Alrial tachyardia 1(2 .5%)
Symptoms during uchycordin
Syncope 14(29%)
Congestive heart failure 15 (31%)
Angina 11(23%)
Dioainess 1908%)
Cardiac arrest 4(8%)
Maximal HR (beatslmin)
177 a 42 (ange 1m-3001
No. ofsymptomatic episodes per week
<c 14(29%)
1-5
20)40%)
5-10
5 )11%)
>50
111120%)
Unsuccessful drugs
Digitalis 43 (88%)
Calcium channel blockem 43 (88%)
Beta-blockers 42 (85%)
Procainamide 39(79%)
Quhadine 38(77%)
Disopyramide 1705%)
Amiodarone 17(35%)
Flewinide 8(16%)
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as the number of hospital admissions per year for any
cardiovascular disorder . In patients complaining of palpita-
tion during the follow-up period, 24 h Holler electrocardio-
graphic (ECG) monitoring was performed . In the event of
death, circumstances surrounding the death were sought and
autopsy results collected.
Eehocardiagraphle measurements . Echocardiographic re-
cordings were analyzed by the use of a computer-assisted
and phantom-calibrated digitization system 471 Freeland
Medical). From two-dimensional measurements, the left
ventricular end-diastolic and end-systolic volames were cal-
culated using a biapical modified Simpson's rule algorithm
(6,7) . Ejection fraction and heart rate ware recorded . The
measurements were made by an investigator
who was un-
aware of patient data . Patients with impaired left ventricular
function (ejection fraction <45%) before ablation underwent
serial echocardiographic studies .
Statistical methods . Comparison
between groups was
performed using a two-sided Student's t test. Actuarial
survival curves were constructed according to the method of
Colton (8) . Comparisons between curves were made both on
a 6 month basis using chi-square analysis and by a compar-
ison of the overall probability of survival using a Cox
proportional hazards model (9). A p value <0 .05 was con-
sidered significant .
Results
Short-Term Outcome After Ablation
The underlying rhythm immediately before ablation was
sinus rhythm in 33 (68%) of the 49 patients and atrial
fibrillation in the remaining 16 patients . The mean unipotar
His bundle amplitude was 0 .36 ± 0.20 mV . The total
delivered energy per patient was 705 ± 360 J, with a mean of
2 .5 ± 0 .9 shocks per patient . Ten patients required three or
more shocks and nine patients (19%) required two ablation
sessions. In seven of these nine patients,complete AV block
could not be achieved and they were discharged with intact
AV conduction.
The mean energy delivered to the 7 patients without
successful ablation was 1,015 ± 130 J versus 661 ± 360 J for
the 42 patients with successful ablation (p < 0.05) . There
was no difference in the recorded His bundle amplitudes
between patients with successful compared with failed abla-
tion (0.37 ± 0 .21 versus 0 .31 ± 0.13 mV . respectively). Five
of the six patients with unsuccessful ablation were men.
Complete AV block with an average escape rate of 37
.5 ± 10
beats/min (range 15 to 56) was achieved in 42 (86%) of the 49
patients.
Complications. Four patients had significant early com-
plications
. One patient, a 59 year old woman with recurrent
atrial fibrillation and mild left ventricular hypertrophy, died
suddenly 2 weeks after ablation . The patient collapsed after
ROSENQVISTETAL,
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Figure 1 . Summary of results of AV junctlonal ablation (abll in 49
patients (pis)
.
CHB = complete heart block ; FU = follovr-up
; prop
= progression: Burg = surgical : sympt improv = symptomatically
improved.
leaving the hospital for a routine check-up and resuscitation
efforts were initiated within approximately 7 min. The initial
ECG showed ventricular fibrillation
. This patient has been
extensively described in an earlier report (10)
.
A second
patient developed hypotension immediately after the abla-
tion procedure but recovered after treatment with intrave-
nous fluids, and one patient
developed clinical signs of
pericarditis with chest pain that resolved spontaneously after
36 h; no pericardial effusion was documented by echocar-
diography . A fourth patient, a 58 year old woman with
ischemic heart disease and frequent ventricular premature
complexes before ablation, had a brief episode of polymor-
phic ventricular tachycardia during intentional inhibition of
her pacemaker 6 h after the ablation . No further episodes of
tachycardia were documented during a follow-up period of 3
years .
rely I_a maa
Long-Term Outcome After Ablation (Fig . 1)
The long-term Follow-up study included 47 patients, with
an average follow-up time of 41 ± 23 months (range 2 weeks
to 90 months) . All survivors were followed up for at least I
year .
Two patients with successful achievement of complete
AV block were lost to follow-up study
.
Recurrence of AV conduction . Atrioventricular conduc-
tion resumed in two patients (4%) who initially had had
successful ablation with recurrence of symptoms . One of
these patients had AV node reentrant tachycardia and the
second had paroxysmal strut fibrillation . These recurrences
of AV conduction occurred after 3 and 6 months, respec-
tively
. One of these patients underwent successful repeat
1470
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catheter ablation
. The other, who had hypertrophic cardio-
myopathy, underwent surgical ablation of the AV junction
along with a myotomy/myectomy procedure at another
institution but died perioperatively from congestive heart
failure.
Among the seven patients who had persistent AV con-
duction at hospital discharge, two developed complete AV
block after4 and 2A months, respectively . Three patients had
improved arrhythmia control with previously ineffective
drugs. Of the remaining two patients, one ultimately re-
sponded to repeat catheter ablation and the other required
surgical division of the His bundle
. Thus, 42 (89 .5%) of the
47 patients had complete AV block produced by catheter
ablation at the end of the follow-up period.
Subsequent cardiovascular events . New onset of conges-
tive heart failure occurred after ablation in four patients; two
had known structural heart disease and two did not . Two
patients developed signs of ischemic heart disease during the
follow-up period . One developed angina pectoris 2 years
after ablation and one had an acute myocardial infarction 14
months after ablation .
Only 2 of the 47 patients were treated with long-term
anticoagulant therapy after ablation . None of the patients
had a cerebrovascular accident, including 27 patients with
chronic or paroxysmal atrial fibrillation . One patient, who
did not receive anticoagulant therapy and had an unsuccess-
ful ablation, had a brachial artery thrombosis 26 months after
ablation.
Drug therapy. Seven of the 42 patients with successful
ablation were treated with cardiac drugs during the follow-up
period . Three patients were treated with quinidine,
flecainide or encainide because of symptomatic premature
ventricular complexes (present before ablation), and four
patients had digitalis, calcium channel blockers or beta-
adrenergic blockers prescribed for ischemic heart disease,
hypertension or congestive heart failure .
Mortality. During the follow-up period, 9 (17%) of the 47
patients died. The causes of death and the clinical charac-
teristics of these patients are presented in Table 2 . Two
patients without significant underlying heart disease died ;
one died suddenly 2 week,. after ablation and the other died
of a subarachnoid hemorrhage 52 months after successful
ablation . Of the seven patients who had unsuccessful abla-
tion (either with early or late failure), two died of congestive
heart failure and two other patients died from noncardiac
causes .
Four of the 12 patients with preexisting heart failure (3
patients in New York Heart Association class III and I
patient in class 11) died of progressive heart failure despite
successful ablation. Survival curves (Fig. 2) show that the
mortality rate was significantly higher among patients with
underlying heart disease .
Table
2, Cause of Death in Nine Patients
AV = atrioventdcular,
COP
= congestive heart failure; CMP = cardie-
myopalhy: COPD = chronic obstructive lungdisease ; EF = ejection fraction;
F = female : FU = follow-up ; RCM = hyperhophic cardiomyopathy
; IHD =
ischemic heart disease; M = male
; SD = sudden death ; SH = subamchnoid
hemorrhage .
Arrhythmic symptoms and results of Halter recordings.
Palpitation during the follow-up period was reported in all 7
patients with unsuccessful ablation compared with I I of 42
patients with successful long-term ablation (p < 0 .05) . Twen-
ty-four hour Holler recordings revealed episodes of so-
praventricular tachycardia in all patients with failed ablation.
In contrast, no tachycardia was observed in the I I patients
with successful ablation but with complaints of palpitation.
In 3 of these 1I patients, palpitation could be ascribed to
premature ventricular complexes ; no cause was found in the
other S.
Echocardiographic findings (Table 3) . Five of the nine
patients with an ejection fraction <45% before ablation
underwent repeat echocardiographic evaluation during the
follow-up period, with a median of 34 months (range 8 to 77)
between investigations. Among the remaining four patients,
Figure 2. Actuarial survival curves for patients undergoing AV
junctional ablation . The upper curve describes the probability of
survival among patients without underlying heap disease and the
lower curve the probability of survival among patients with under-
lying heart disease . See text for discussion .
Cumulative survival
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Follow-up, months
Age
(yr)1
Gender
Cardiac
Diagnosis
EF
190)
Chronic
AV Block
FU
(am)
Cause or
Death
731M DID - Yes 2 tan
791F
CMP 55
Yes 5 CHF
48)M No 60 Yes 52 SH
301M HCM 55 No 36 CHF
61/M COPD 47 Yes 40 COPD
421M DID 55 Yes 36 Cancer
581F No 60 Yes I SD
691M CMP - Yes 52 CHF
63/M CMP 40 No 36 CLIP
Mean 58 .1 53 .1 29
TSD 016 -7 ±21
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Table 3. Changes in Left Ventricular End-Diastolic Diameter and Ejection Fraction Before and
After Ablation in Five Patients
HYHA
I
11
III
Iv
AF = permanent a trial fibn1lntioe : Dv = diagnasi : HR = heart rate : LV ;D = left ventricular end-diastolic
volume: PAF - paroxysmal anal fibrillation : Pre = before:Post = after: SHD = arucmrnl heart disease : SSS = sick
sinus syndrome: other abbreviations as in Tables
I end
2 .
one had had an unsuccessful ablation, one was lost to
follow-up, one refused follow-up evaluation and one died of
ischemic heart disease during the follow-up period .
Four of these five patients with a low ejection fraction
before ablation showed significant improvement during long-
term follow-up. The median ejection fraction was 24% (range
20% to 35%) before ablation and 50% (range 21% to 58%)
after ablation (p < 0.05). The heart rate at the two evalua-
tions was comparable in four of the five patients (82 ± 10
versus 75± beats/min) . In the fifth patient, the heart rate was
134 beats/min before ablation and 70 beats/min 8 months
after ablation.
Among the four patients who showed an improvement in
ejection fraction, functional class improved in three and
remained unchanged in one, whereas functional class dete-
riorated in the patient who had an unchanged ejection
fraction . Figure 3 summarizes changes in functional class
Figure 3. Changes in New York Heart Association (NYHA) func-
tional class in patients with preexisting heart failure during the
follow-up period .
nelora Ablation
Attar
ammo
0
among patients with preexisting heart failure .
Changes in life-style. An improved activity level was
reported by 35 (83%) of the 42 patients with successful
ablation . Seven patients considered their condition un-
changed and one felt worse than before ablation . When
separating the patients into those with and without preexist-
ing heart disease, 10(67%) of the 15 patients with preexisting
heart disease reported an improved activity level after abla-
tion as compared with 25 (89%) of 28 without preexisting
heart disease (p < 0.01) .
In the I I patients with preexisting heart failure and a
successful ablation, the functional class improved in 3,
remained unchanged in 3 and deteriorated in 5 .
Health care utilization manifested as the number of
hospital admissions per year before and after ablation
showed a significant decrease after ablation (2
.4' 2 .0 versus
0.3 ± 0 .5 admissions per year, p < 0 .001).
Pacemaker fallow-up (Fig . 4) . A ventricular pacemaker
(VVI) without rate response was implanted in 27 patients
(65%), a ventricular pacemaker with rate response (VVI-R)
in 8 patients (17
.5%) and an AV sequential pacemaker
(DDD) in 8 patients (17.5%) .
During the follow-up period, 9 (33%) of the 27 patients
with a VVI pacemaker underwent revision . One received a
DDD and eight received a VVI-R pacemaker . The patient
who received the DDD unit had complained of symptoms
compatible with pacemaker syndrome with her VVI unit .
One of the eight patients with a VVI-R pacemaker had his
unit replaced with a DDD unit because of the pacemaker
syndrome . Two of the eight patients who initially received a
DDD unit had it replaced by a VVI-R unit because of
symptoms of supraventricutar tachycardia caused with
tracking of the atria) rate. Another two patients with a
concealed accessory pathway and a DDD pacemaker had
documented pacemaker-mediated tachycardia that could be
avoided by prolonging the atria] refractory period . The
Age (yell
Gender SHD
FU
1ma) Dv
LVED
lent
HR
Iheaten/el
LaSF
l%1
Pre Poct Pre Punt Pre
V-
65lF IHD 25 SSS 6 S9 50 20 0
601M None 9 ME
7
901 71 23
531M None 34 AVNRT 77 g0 74
2WM Non, R PAF 70 34 58
711M None AF - 711 70 15 51
Mean 55 92 74 45
P
c 0.05
ODD 17 28 7
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Figure 4 . Changes in pacemaker mode during the follow-up period.
DDD = atrioventricutar sequential pacemaker ; VVI and
VVIR =
ventricular pacemaker without and with rate response, respectively .
'Two generators had to be reprogrammed to avoid pacemaker-
mediated tachycardia
.
remaining four patients with a ODD generator had their
pacemaker programmed in the DDD mode during the fol-
low-up period
.
One patient had premature acute complete battery failure
and developed symptoms of fatigue associated with an
idioventricular rhythm of 40 beats/min and underwent un-
eventful generator replacement .
Discussion
In previous reports
(1-4,11), marked variability in the
successful induction of complete heart block using direct
current catheter ablation has been documented . The largest
experience to date comes from the voluntary worldwide
registry (5) in which the incidence of chronic complete AV
block was 64% . The present report suggests that centers
performing a large number of these procedures should
expect an efficacy rate in the range of 90%. Of note was the
late development of complete AV block in two of six patients
in whom this procedure was originally unsuccessf.d . This
finding suggests the need for long-term pacemaker support
even in those patients without persistent complete AV block
after ablation
.
Changes in lifestyle before and after ablation, Kay et al .
(12) reported an overall improved quality of life in 12
consecutive patients with paroxysmal Burial fibrillation who
were assessed prospectively with a self-administered ques-
tionnaire before and 6 weeks after ablation . Changes in
functional capacity correlated strongly with changes in
treadmill exercise duration
. In our present study, 88% of the
patients who had permanent complete AV block reported
improved activity levels
. This improvement was more pro-
pounced among patients without preexisting structural heart
disease . This finding is in agreement with the suggestion of
Kay et al . (12) that patients without underlying structural
heart disease would benefit .-rare than other groups from
ablation therapy . It is also supported by the absence of a
significant change in functional capacity, as assessed by the
New York Heart Association classification, in patients with
preexisting heart failure and structural heart disease .
Changes in myocardial function after catheter ablation . It
is well appreciated that persistent tachycardia may result in
myocardial dysfunction ; less well documented is reversal of
myocardial dysfunction after successful control of
the ar-
rhythmia . McLaran et al . (13) described four pediatric pa-
tients with supraventricular arrhythmias and depressed left
ventricular ejection fraction who underwent serial echocar-
diographic investigations before and after pharmacologic
control of their tachycardia. All four patients showed
markeo improvement in ejection fraction after their arrhyth-
mia had been brought under control . Similarly, Packer et al.
(14) described eight patients (aged 6 to 57 years) with
incessant or frequent supraventricular arrhythmia and a
depressed ejection fraction who underwent catheter or sur-
gical ablation of the AV junction . Radionuclide angiography
performed at baseline and early (5 to 14 days) and late (4 to
40 months) after ablation showed that the ejection fraction
increased significantly soon after ablation . At late evalua-
tion, a further although nonsignificant increase in ejection
fraction was noted. Similar findings were reported by Gil-
lette et al
. (15) among 10 pediatric patients who underwent
surgical ablation of ectopic atria) tachycardia foci .
A limitation of all these studies is that the ejection
fraction was assessed at markedly different heart rates
before and after ablation . For example, in the study of
Packer et al. (14), only one of the eight patients was assessed
at a comparable heart rate in the preablation and early and
late postablation studies
. Because it is well known (16) that
ejection fraction diminishes with increased heart rate, it is
difficult to draw any firm conclusions from these studies
(13-16) regarding the long-term effect of supraventricular
tachycardia on myocardial function.
In a preliminary report from our laboratory (17) of pa-
tients undergoing catheter ablation
of
the AV junction, we
found no significant change in the mean ejection fraction
before or after ablation . In the present review, we performed
serial echocardiographic studies in five patients with a
depressed ejection fraction ; serial measurements were per-
formed over a median of 34 months after ablation. A
significant improvement in ejection fraction was found in
four of the five patients, whereas in the fifth patient, the
ejection fraction remained virtually unchanged . The heart
rate at the two evaluations was virtually the same in four of
the patients, and the changes in ejection fraction correlated
well with changes in functional class .
Conclusions relative to changes
in
ejection fraction after
JACC Val . 16, No . 6
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ablation remain tentative because serial echocardiagraphic
studies were not available in four of nine patients with
depressed left ventricular function at baseline
. Our prelimi-
nary findings suggest the need for prospective evaluation of
this important issue in a larger patient cohort .
Development of. symptoms and objective signs fconges-
tive heart failure after ablation occurred mainly in patients
with either preexisting heart disease or with unsuccessful
ablation, indicating that the ablative procedure itself rarely
caused any short-or long-term myocardial dysfunction
. Two
patients without structural heart disease developed new
onset of congestive heart failure during the follow-up period .
In these patients, the arrhythmia may have been an early
manifestation of a cardiomyopathic process. We cannot
exclude the possibility that heart failure may have been due
to the ablation procedure or to an unphysiologic activation
pattern caused by ventricular pacing (18) .
Adverse effects associated with ablation. In this study .
three patients suffered serious complications in association
with the ablative procedure . One patient with idiopathic
cardiomyopathy died suddenly 2 weeks after a successful
ablation . Autopsy showed marked fibrosis and inflammatory
changes at the summit of the ventricular septum, which may
have been the nidus for malignant ventricular arrhythmias.
Data from the Percutaneous Cardiac Mapping and Ablation
Registry (5) have documented eight episodes (1 .8%) of
sudden death among a total of 480 patients in whom mortal-
ity statistics are known . In all but one instance, these deaths
occurred within 6 months after attempted ablation . How-
ever, the reported 1 .8% incidence rate of sudden death
emphasizes the importance of reserving this procedure only
for patients with severe supraventricular arrhythmias who
do not respond to conventional drug treatment .
One patient experienced an episode of nonsustained
polymorphic ventricular tachycardia (torsade de pointes) 6 h
after ablation . This arrhythmia was clearly initiated by
bradycardia and has not recurred with consistent pacing at a
rate of 80 beats/min
. Nonsustained ventricular arrhythmias
have been reported in 3 .5% of patients undergoing direct
current ablation in the Percutaneous Cardiac Mapping and
Ablation Registry (5) . Potymorphic ventricular tachycardia
in three patients shortly after the ablation procedure during
intentional pacemaker inhibition was recently reported (19).
One patient experienced transient symptomatic hypoten-
sion after ablation that required pressor support and one
patient developed pericarditis with chest pain that resolved
without treatment . Both these complications have been
reported in the Percutaneous Cardiac Mapping and Ablation
Registry report (5) . Although only 2 of 47 patients received
long-term anticoagulant therapy, only I patient developed
systemic embolism. Of the 29 patients with chronic or
paroxysmal atrial fibrillation or flutter who were followed up
for 843 patient-months none developed systemic embolism .
In contrast, other reports (20) of systemic embolism in
1473
patients with nonrheumatic atrial fibrillation suggest a pro-
jected incidence of two to three episodes of stroke for this
group of patients.
Arrhythmic symptoms despite successful abtatien
. A new
finding was the occasional occurrence of palpitation in
almost 25% of patients who achieved chronic complete AV
b lock . i n these patients, repeat 24 h ambulatory ECG
recordings showed that the symptoms were either due to
premature ventricular complexes or were not associated
with any arrhythmia disturbance . The latter finding may be
expected in patients sensitized by long-term abnormalities in
heart rhythm 121)
.
Choosing the optimal pacemaker made after ablation . Our
experience suggests that great care is needed in the choice of
the cardiac pacing mode in patients who have had successful
AV junction ablation. Approximately 20% of our patients
who originally received a ventricular-inhibited (VVI) pace-
maker had this unit replaced with a rate-responsive unit
(VVI-R) because of symptoms related to a low exercise
capacity. This finding is also in agreement with the work of
Kay et al . (12). who noted improved exercise capacity after
ablation in patients with paroxysmal atria) fibrillation who
received a ventricular rate-responsive pacemaker after a
successful ablation procedure .
Four of eight patients with an AV sequential (DDD)
pacemaker had to have the unit replaced or reprogrammed
either because of tachycardia associated with a concealed
accessory pathway or because of tracking of faster atria)
rhythms in the patients with persistent paroxysmal su-
praventricular tachycardia
. This finding emphasizes that a
dual chamber pacemaker probably should not be the first
choice in patients who have undergone ablation because of
supraventricular arrhythmias . However, in a subset of pa-
tients (for example, those with hypertrophic cardiomyopa-
thy), the advantages of AV synchronous pacing may out-
weigh these disadvantages
. These observations were made
before availability of DDI-R mode programming, a mode of
pacing that may he particularly effective for those with
chronic complete AV block and recurrent paroxysmal su-
praventricular arrhythmias .
Summary and clinical implications . We report our long-
term experience with catheter ablation of the AV junction in
patients with drug-resistant supraventricular tachycardia . In
contrast to previous reports, our success rate for achieving
complete AV block with the catheter technique was 88%.
The vast majority of patients, particularly those without
organic heart disease, reported an improved quality of life
after the procedure . In addition, we document a dramatic
decrease in health care costs in terms of reduction in need
for antiarrhythmic drugs as well as in need for hospitaliza-
tion for cardiac-related problems .
Two observations related to heart rate control are par-
ticularly intriguing
. In a limited subset of patients, the
ejection fraction tended to increase in those with depressed
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left ventricular function at baseline, suggesting that im-
proved rate control may reverse changes due to a tachy-
cardic myopathy for at least some of our patients with left
ventricular dysfunction . In addition, in the follow-up evalu-
ation of 29 patients with paroxysmal or chronic atrial fibril-
lation, none with chronic AV block had systemic embolism,
suggesting that rate control may be an important factor in
preventing development of cardiac thrombus . Although no
procedure-related deaths were detected, one patient died
suddenly 2
weeks after ablation. Therefore, it should be
emphasized that this procedure should be limited to patients
with drug-resistant disabling arrhythmias
. The recent intro-
duction of radiofrequency energy for catheter ablation (22)
might avoid some of the adverse effects seen with direct
current ablation.
Long-term pacing should trobably be initiated even for
those with failed ablative atlr'mpts because in our experi-
ence, one-third (two of six) of these patients developed late
AV block. Great care must be taken in the choice of the
optimal pacing mode for these patients
. Our current experi-
ence suggests that rate-responsive ventricular pacing seems
adequate for most patients apart from those with largely
intact sinus function who are dependent on AV synchrony
for optimal cardiac function .
The
clinical decision relative to choice of drug versus
ablative therapy is individualized, taking into account symp-
toms (including need for resuscitation), response to prior
drug therapy (including the risk of proarrhythmic effects),
presence of associated cardiac disease and the patient's
desire to be free of lifelong drug therapy . Balanced against
the potential adverse effects and the need for long-term
pacing after catheter ablation are the advantages
of more
consistent arrhythmia control, improved quality
of life for
the vast majority of patients, less expense relative to the cost
of drugs, hospital and emergency visits and the possibility
of
improved cardiac output in those with depressed left ven-
tricular function .
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